Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype

Haematologica

Volumn 100, Issue 9, 2015, Pages e351-e353

  Ahn, Jae Sook ^a   Kim, Hyeoung Joon ^a   Kim, Yeo Kyeoung ^a   Jung, Sung Hoon ^a   Yang, Deok Hwan ^a   Lee, Je Jung ^a   Lee, Il Kwon ^a   Kim, Nan Young ^a   Minden, Mark D ^b   Jung, Chul Won ^c   Jang, Jun Ho ^c   Kim, Hee Je ^d   Moon, Joon Ho ^e   Sohn, Sang Kyun ^e   Won, Jong Ho ^f   Kim, Sung Hyun ^g   Kim, Namshin ^h   Yoshida, Kenichi ⁱ   Ogawa, Seishi ⁱ   Kim, Dennis Dong Hwan ^b  

^a Chonnam National University Research Institute of Medical Sciences   (South Korea)

^b UNIVERSITY OF TORONTO   (Canada)

^c Samsung Medical Center   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Kyungpook National University Hospital   (South Korea)

^f Soonchunhyang University College of Medicine   (South Korea)

^g Dong A University College of Medicine   (South Korea)

^h Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

ⁱ KYOTO UNIVERSITY   (Japan)

Author keywords

Acute myeloid leukemia; Homozygous mutation; Normal karyotype; TET2

Indexed keywords

CD135 ANTIGEN; NUCLEOPHOSMIN; PROTEIN; TEN ELEVEN TRANSLOCATION ONCOGENE FAMILY MEMBER 2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; AGE; BLOOD ANALYSIS; EVENT FREE SURVIVAL; HOMOZYGOSITY; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MUTATION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; RECURRENCE RISK; RISK FACTOR; SEQUENCE ANALYSIS; ADOLESCENT; ADULT; DISEASE FREE SURVIVAL; EVALUATION STUDY; FEMALE; FOLLOW UP; GENETICS; HOMOZYGOTE; HUMAN; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADOLESCENT; ADULT; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HOMOZYGOTE; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; SURVIVAL RATE;

EID: 84940934516     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.126227     Document Type: Letter

References (15)

1. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011;29(10):1373-1381
2. Gaidzik VI, Paschka P, Spath D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol. 2012;30(12):1350-1357
3. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553-567
4. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839-843
5. Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia. 2014;28(3):485-496
6. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11-24
7. Ko M, Bandukwala HS, An J, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci USA. 2011; 108(35):14566-14571
8. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011;118(17):4509-4518
9. Chou WC, Chou SC, Liu CY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118(14):3803-3810
10. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474
11. Nibourel O, Kosmider O, Cheok M, et al. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010;116(7):1132-1135
12. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838-842
13. Kim YK, Kim HN, Lee SR, et al. Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol. 2010;45(1):36-45
14. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-1089
15. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011; 364(26):2496-2506.